ceritinib
Interviews and expert commentary tagged “ceritinib” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
ALK—Targeted Lung Cancer Drugs Benefited Real World Patients
MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK ge
7 November 2018
9 minutes
Audio Journal of Oncology
Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer
MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSC
27 October 2018
7 minutes
Audio Journal of Oncology
Second-Generation ALK Inhibitor = Longer PFS in ALK+ Lung Cancer After Crizotinib
COPENHAGEN—Longer progression free survival (PFS) was achieved in patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib randomised to treatment with the se
8 December 2016
8:52 secs